DUBLIN, May 10, 2010 (BUSINESS WIRE) -- Research and Markets (http://www.researchandmarkets.com/research/98d539/erectile_dysfuncti) has announced the addition of GlobalData's new report "Erectile Dysfunction - Drug Pipeline Analysis and Market Forecasts to 2016" to their offering.
Erectile Dysfunction - Drug Pipeline Analysis and Market Forecasts to 2016 is an essential source of information and analysis on the global erectile dysfunction market. The report identifies the key trends shaping and driving the global erectile dysfunction market. The report also provides insight on the prevalent competitive landscape and the emerging players expected to bring significant shift in the market positioning of the existing market leaders. Most importantly, the report provides valuable insight on the pipeline products within the global erectile dysfunction sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GlobalData's team of industry experts.
The Erectile Dysfunction Market is forecast to decline until 2016 The Erectile Dysfunction (ED) market is currently very competitive and is expected to become more competitive in the future. The market is dominated by three major cyclic guanosine monophosphate (cGMP)-specific phosphodiesterase type 5 (PDE5 inhibitors) including Viagra (sildenafil citrate), Cialis (tadalafil) and Levitra (vardenafil HCl). The market is expected to witness a decline between 2011 and 2014 due to patent expiry of a blockbuster drug used in the treatment of ED. The major drug, Viagra's (sildenafil citrate) patent expires in early 2012 and the market is expected to decline due to erosions of margins with the entry of generics. Post 2014, the market is expected to grow due to increase in the number of ED patients. The currently marketed products for the treatment of ED have high efficacy and safety standards. The market also has two other modes of treatment including Vacuum Constriction Device (VCD), Penile Prosthesis, and Vascular Reconstructive Surgery. The ED diagnosis rate is low due to non availability of formal tests. The other important factors are lack of knowledge among patients regarding ED and reluctance in sharing sexual problems with physicians and partners. The unmet need in ED is low to moderate as a significant number of patients do not respond to currently available treatment. Therefore, patients not responding to current treatment would still remain an untapped area of research and development for the pharmaceutical companies to bring novel drugs into the market. It would, therefore, be sufficient for newer entrants to demonstrate superior efficacy and safety profile in order to capture value in the market over the currently used branded treatments.
Author's analysis estimates that Avanafil is likely to get market approval as the drug is expected to bring higher efficacy and safety measures in the treatment of ED. Avanafil is a PDE5 inhibitor, which is already available in the market in the form of Viagra, Cialis and Levitra. Therefore Avanafil is expected to face stiff competition in the market. Increase in treatment seeking population, prescription rates and ageing global population are considered to be important drivers for this market. GlobalData's analysis shows that the market grew at a Compound Annual Growth Rate (CAGR) of 9.8% from $1,366 m in 2001 to $2,884 m in 2009. The market is predicted to decline at a CAGR of 4% from 2009 and reach a total value of $2,165 m by 2016. The decline in the market is primarily attributed to the patent expiry of a major marketed product, Viagra, in 2012. The decline in market can also be attributed to weak pipeline as no major product is likely to surpass the efficacy of the currently marketed product.
Global Erectile Dysfunction Market Forecast 2001-2016 Scope Annualized global ED therapeutics market revenues data from 2001 to 2009, forecast forward for seven years to 2016. Geographies covered in this report include the US, the UK, Italy, Spain, Germany, France, and Japan. Pipeline analysis data providing an overview of different phases, mechanisms of action being developed, and emerging trends. Key classes of mechanism of action include FKBP12 binder, serotonin and dopamine enhancer, PDE-5 inhibitor, and Alpha1A-adrenoreceptors antagonist. Analysis of the current and future market competition in the global ED therapeutics market. Key market players covered are VIVUS, Inc., and Rexahn Pharmaceuticals, Inc. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications. Key topics covered include strategic competitor assessment, market characterization, unmet needs, and the implications for the future market associated with ED.
Reasons to buy Develop and design your in-licensing and out-licensing strategies through review of pipeline products and technologies and by identifying companies with the most robust pipeline. Develop business strategies by understanding the trends shaping and driving the global erectile dysfunction market. Drive revenues by understanding key trends, innovative products and technologies, market segments and companies likely to impact the global erectile dysfunction market in future.
Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships. What's the next big thing in the global erectile dysfunction market landscape? - Identify, understand and capitalize.
Key Topics Covered: Erectile Dysfunction: Market Characterization Erectile Dysfunction: Competitive Assessment Erectile Dysfunction: Pipeline Assessment Erectile Dysfunction Market: Implications for Future Market Competition Erectile Dysfunction Market: Future Players in the Erectile Dysfunction Market Erectile Dysfunction: Appendix Companies Mentioned: VIVUS, Inc. Rexahn Pharmaceuticals, Inc.
For more information visit http://www.researchandmarkets.com/research/98d539/erectile_dysfuncti SOURCE: Research and Markets CONTACT: Research and Markets Laura Wood, Senior Manager press@researchandmarkets.com U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716 Copyright Business Wire 2010 -0- INDUSTRY KEYWORD: Health
Pharmaceutical
General Health